Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

British Journal of Cancer

Volumn 79, Issue 2, 1999, Pages 286-292

  Engblom, P ^a,b   Rantanen, V ^a,b   Kulmala, J ^a   Helenius, H ^b   Grenman S ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Chemosensitivity; Cisplatin; Interaction; Ovarian carcinoma; Taxanes

Indexed keywords

CISPLATIN; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0032944148     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690046     Document Type: Article

References (35)

1. Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-893
2. Arbuck SG, Canetta R and Onetto N (1993) Current dosage and scheduling issues in the development of paclitaxel (TAXOL). Semin Oncol 4 (suppl. 3): 31-39
3. Burris HA, Fields S and Peacock N (1995) Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 22: 35-40
4. Chou TC, Otter GM and Sirotnak FM (1996) Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37: 222-228
5. Citardi MJ, Rowinsky EK, Schaefer KL and Donehower RC (1990) Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. Proc Am Assoc Cancer Res 34: 2431
6. Díaz JF, Menendez M and Andreau JM (1993) Assembly of purified GDP-tubulin into microtubules induced by RP 56976 and paclitaxel: reversibility, ligand stoichiometry and competition. Biochemistry 32: 2747-2755
7. Engblom P, Rantanen V, Kulmala J and Grènman S (1996) Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res 16: 1743-1748
8. Engblom P, Rantanen V, Kulmala J, Heiskanen J and Grenman S (1997) Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res 17: 2475-2480
9. Fogh J, Wright WC and Loveless JD (1977) Absence of Hela cell contamination on 169 cell lines derived from human tumours. J Natl Cancer Inst 58: 209-214
10. Georgiadis MS, Russell E and Johnson BE (1994) Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc Int Assoc Study Lung Cancer 11: 95
11. Grènman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE (1989) Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136
12. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Potier P (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-998
13. Gullo JJ, Litterst AR, McGuíre WP, Sikic B, Hoth J and Wooley PA (1980) Pharmacokinetics and protein-binding of cis-dichlorodiamineplatinum (II) administered as a one hour or as a twenty-four hour infusion. Cancer Chemother Pharmacol 5: 21-26
14. Hill BT, Whelan RDH, Shellard SA, McClean S and Hosking LK (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182
15. Hino M, Kobayashi K, Hayashihara K, Aoyama A, Shibuya M and Kudo S (1995) In vitro combination effect of docetaxel (RP 56976) with vinca alkaloids on cancer cell line. Proc Am Assoc Cancer Res 36: 2995
16. Huizing MT, Keung ACF and Rosing H (1993) Pharmacokinetics of paclitaxel and metabolites in a randomised comparative study in platinum-pre-treated ovarian cancer patients. J Clin Oncol 11: 2127-2135
17. Jekunen A, Christen R, Shalinsky D and Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma in vitro. Br J Cancer 69: 299-306
18. Kaye SB, Piccart M, Aapro M and Kavanagh JJ (1995) Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 31A: 14-17
19. Kelland LR and Abel G (1992) Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450
20. Kiyozuka Y, Nishimura H, Nakashima A, Imamura K, Ota S, Yakushiji OM, Imai S and Morimatsu M (1995) In vitro cytotoxicity on ovarian cancer of low-dose continuous exposure to microtubule inhibitors (paclitaxel/taxotere) combined with cisplatin. Oncol Rep 2: 517-523
21. Koechli O, Sevin B-U, Perras J, Chao Chou T, Angioli R, Steren A, Untch M and Averette HE (1993) Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treatment 28: 21-27
22. Lavelle F, Bissery M-C, Combeau C, Riou JF, Vrignaud P and Andrè S (1995) Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22: 3-16
23. Lopes NM, Adams EG and Pitts TW (1993) Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242
24. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
25. Parker R, Lee KB and Dabholkar M (1993) Influence of taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 34: 2122
26. Piccart MJ, Bertelsen K and Stuart G (1997) Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOVOCA, NCI-C and Scottish Intergroup experience. Proc Am Soc Clin Oncol 16: 352a
27. Rantanen V, Grènman S, Kulmala J and Grènman R (1994) Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482-486
28. Riou JF, Naudin A and Lavelle F (1992) Effects of taxotere on murine and human tumour cell lines. Biochem Biophys Res Commun 187: 164-170
29. Riou JF, Petingenet O, Combeau C and Lavelle F (1994) Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35: 384
30. Rowinsky EK, Donebower RC and Jones RJ (1988) Microtubule changes and cytotoxicity in leukaemia cell lines treated with Taxol. Cancer Res 48: 4093-4100
31. Saunders DE, Christensen C and LoRusso PM (1992) Inhibition of ovarian carcinoma cells by taxol combined with vitamin D and adriamycin. Proc Am Assoc Cancer Res 33: 2641
32. Schiff PB, Gubits R and Kasbimawo (1995) Paclitaxel with ionising radiation. In Paclitaxel in Cancer Treatment, McGuire WP and Rowinsky EK (eds), pp. 81-90. Marcel Dekker: New York
33. Thigpen JT, Blessing JA, Vance RB and Lambuth BW (1989) Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 16: 58-65
34. Thilly WG, Deluca JG, Furth EE, Hoppe H, Kaden DA, Krolenski JJ, Liber HL, Skopek TR, Laslapikoff SA, Tizard RJ and Penman BW (1980) Gene-locus mutation assays in diploid human lymphoblast lines. In Chemical mutagens, de Serpes FJ and Hollander A (eds), pp. 331-364. Plenum: New York
35. Untch M, Sevin B-U, Perras JP, Angioli DR, Untch A, Hightower RD, Koechli O and Averette HE (1994) Evaluation of paclitaxel (Taxol), cisplatin and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP-cell viability assay. Gynecol Oncol 53: 44-49